Furthermore, studies have shown that HDAC inhibition can alter the tumor cell phenotype, increase the expression of NK-activating ligands, and promote NK cell-mediated killing, suggesting a potential strategy for combination treatment [17–25]. Here, HDAC9 is linked to neoplasm.